Abstract
Familial dysautonomia (FD) is an autosomal recessive disorder marked by developmental and progressive neuropathies. It is caused by an intronic point mutation in the inhibitor of kappa B kinase complex-associated protein (IKAP, also called ELP1) gene IKBKAP/ELP1, a component of the Elongator complex. Due to variation in tissue-specific splicing, the mutation primarily affects the nervous system. One of the most debilitating hallmarks of FD that affects patients’ quality of life is progressive blindness. To determine the pathophysiological mechanisms that are triggered by the absence of IKAP in the retina, we generated retina-specific Ikbkap conditional knockout (CKO) mice using a Pax6-Cre, which abolished Ikbkap expression in all the cell types of the retina. Although sensory and autonomic neuropathies in FD are known to be developmental in origin, the loss of IKAP in the retina did not affect its development, demonstrating that IKAP is not required for retinal development. The loss of IKAP caused progressive degeneration of retinal ganglion cells (RGCs) by 1 month of age. Mitochondrial membrane integrity was breached in RGCs, and later in other retinal neurons. In CKO retinas, mitochondria were depolarized, and Complex I function and ATP were significantly reduced. While mitochondrial impairment was detected in all Ikbkap-deficient retinal neurons, RGCs were the only cell type that degenerated, with the survival of other retinal neurons unaffected. Together, this retina-specific FD model is a useful in vivo model for testing potential therapeutics for mitigating blindness in FD, and our data indicate that RGCs and mitochondria are promising targets.
- Received January 22, 2018.
- Accepted June 12, 2018.
- © 2018. Published by The Company of Biologists Ltd
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Article navigation
Related articles
Cited by...
More in this TOC section
Similar articles
Other journals from The Company of Biologists
Minifocus – Gene-edited zebrafish models take disease research to the next level
The potent combination of CRISPR/Cas9 and zebrafish as a model organism offers enormous potential for research into human diseases caused by point mutations. Three new articles published in DMM from the labs of Lisa Maves, Jeroen Bakkers and Andy Willaert use zebrafish to explore how advances in CRISPR/Cas9 optimisation offer a new level of accuracy and specificity previously out of reach for research into this type of human genetic disorder. A new Editorial by Sergey Prykhozhij and Jason Berman examines the implications of these articles in the progression of zebrafish knock-in models, the advantages and challenges of working with such precise mutants, and the translational relevance of these models for human disease research.
At a glance – Immune regulation of metastasis: mechanistic insights and therapeutic opportunities
In a new Review and accompanying poster, Olga S. Blomberg, Lorenzo Spagnuolo and Karin E. de Visser discuss the dual role of the immune system in metastasis and summarize promising therapeutic strategies to target tumor-immune interactions.
Editor's choice – Apolipoprotein E deficiency accelerates atherosclerosis development in miniature pigs
In our newest Editor's choice article, Yifan Dai and colleagues describe an ApoE knockout minipig model that displayed severe hypercholesterolemia and spontaneously developed human-like atherosclerotic lesions in the aorta and coronary arteries within 6 months of feeding on a high-fat and high-cholesterol diet.
First Person interviews
Have you seen our interviews with the early-career first authors of our papers? Recently, we caught up with first authors Annekatrien Boel and Georgina Askeland.
Journal meeting – Blood disorders: models, mechanisms and therapies
Register your interest in our upcoming meeting on blood disorders and their treatment, organised by DMM Editor-in-Chief Monica Justice, Nancy Speck, Paresh Vyas and Leonard Zon. The meeting will bring together diverse front-line researchers, stimulating discussions across basic research and clinical disciplines, and fostering collaborative links among researchers.
Why should you publish your next paper in DMM?
DMM aims to promote human health by encouraging collaboration between basic and clinical researchers, covering a diverse range of diseases, approaches and models. Our Editors are all active researchers in the field – your peers, colleagues and mentors, who know how much work has gone into every paper. Recently, we have introduced format-free submission, and we accept peer review reports from other journals, making submission as easy as possible for our authors. Send us your next great paper – publish with us and you'll be in good company.
preLights – Switching melanoma behaviour with STAT3
Hannah Brunsdon highlights a recent preprint from Richard Moriggl and colleagues showing that STAT3 represses the MITF pathway to drive metastasis in melanoma. The preprint also emphasises that there are huge challenges ahead in correctly balancing and timing drug treatment to prevent unwanted activation of genes which can exert large effects on tumour growth and survival.
Back in July, Hannah also highlighted the preprint from the Maves lab that is now published in DMM and features in our minifocus on CRISPR-generated zebrafish models.
Catch up with recent preLights selected for the translational biology community in our latest Table of Contents.